, Tracking Stock Market Picks
Enter Symbol:

down 79.62 %

CELSION CORP (CLSN) rated Buy with price target $7 by Brean Murray

Posted on: Thursday,  Feb 16, 2012  8:25 AM ET by Brean Murray

Brean Murray rated Buy CELSION CORP (NASDAQ: CLSN) on 02/16/2012, when the stock price was $9.77. Since
then, CELSION CORP has lost 79.62% as of 01/19/2016's recent price of $1.99.
If you would have followed this Brean Murray's recommendation on CLSN, you would have lost 79.62% of your investment in 1433 days.

Celsion Corporation (Celsion) is an oncology drug development company focused on developing drugs for the treatment of various cancer indications. The Company?s product ThermoDox is evaluated in a Phase III clinical trial for primary liver cancer and a Phase II study for recurrent chest wall breast cancer (RCW). ThermoDox is a liposomal encapsulation of doxorubicin, an oncology drug for the treatment of a range of cancers.

Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients. Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion. Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage. Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients. Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/16/2012 8:25 AM Buy
9.77 31.50
as of 12/31/2012
1 Week down  -3.19 %
1 Month up  9.20 %
3 Months up  50.55 %
1 YTD up  277.41 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy